News & Events

Press Releases

Former Pfizer R&D President Joins Frequency Therapeutics’ SAB

 

WOBURN, Mass., March 30, 2017 – Frequency Therapeutics, a company developing a pipeline of drugs by activating progenitor cells within the body, today announced the appointment of John LaMattina, Ph.D. as a Senior Advisor to the CEO, and a member of the Scientific Advisory Board.

“As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise,” said David Lucchino, President, Co-Founder and CEO of Frequency. “John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”

Dr. LaMattina previously was President of Pfizer Global Research and Development and Senior Vice President of Pfizer, Inc. During Dr. LaMattina’ s leadership tenure, Pfizer discovered and developed several important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. Dr. LaMattina is the author of numerous scientific publications and U.S. patents, and is the author of “Drug Truths: Dispelling the Myths About Pharma R&D.” He currently serves as an Independent Non-Executive Director at PureTech Health.

“It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss,” said Dr. LaMattina. “The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new disease-modifying therapies for hearing and other areas throughout the body.”

ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. www.frequencytx.com.

Media Inquiries:
Stefanie Tuck or Kari Watson
MacDougall Biomedical Communications
+1 781-235-3060
frequencytx@macbiocom.com